The Hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer

Cancer Immunology, Immunotherapy

Volumn 62, Issue 6, 2013, Pages 1029-1039

  Onishi, Hideya ^a   Morisaki, Takashi ^b   Kiyota, Akifumi ^b   Koya, Norihiro ^b   Tanaka, Hiroto ^b   Umebayashi, Masayo ^b   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Fukuoka General Cancer Clinic   (Japan)

Author keywords

Activated lymphocytes; Advanced cancer; Cyclopamine; Hedgehog signaling; Hypoxia

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPAMINE; GAMMA INTERFERON; NATURAL KILLER CELL RECEPTOR NKG2D; SONIC HEDGEHOG PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; HEDGEHOG PROTEINS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MICE; MIDDLE AGED; NATURAL KILLER T-CELLS; NEOPLASM STAGING; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VERATRUM ALKALOIDS;

EID: 84878861590     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1419-5     Document Type: Article

References (31)

1. Ingham PW, McMahon AP (2001) Hedgehog signaling in animal development: paradigms and principles. Genes Dev 15:3059-3087
2. Cohen MM Jr (2003) The hedgehog signaling network. Am J Med Genet A 123:5-28
3. Pasca di Magliano M, Hebrok M (2003) Hedgehog signaling in cancer formation and maintenance. Nat Rev Cancer 3:903-911
4. Nagai S, Nakamura M, Yanai K, Wada J, Akiyoshi T, Nakashima H et al (2008) Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Cancer Sci 99:1377-1384
5. Souzaki M, Kubo M, Kai M, Kameda C, Tanaka H, Taguchi T et al (2011) Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer. Cancer Sci 102:373-381
6. Onishi H, Katano M (2011) Hedgehog signaling pathway as a therapeutic target in various types of cancer. Cancer Sci 102:1756-1760
7. Tremblay MR, Nesler M, Weatherhead R, Castro AC (2009) Recent patents for hedgehog pathway inhibitors for the treatment of malignancy. Expert Opin Ther Pat 19:1039-1056
8. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L et al (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361:1173-1178
9. Tremblay MR, Lescarbeau A, Grogan MJ (2009) Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 52:4400-4418
10. Low JA, de Sauvage FJ (2010) Clinical experience with hedgehog pathway inhibitors. J Clin Oncol 28:5321-5326
11. Atwood SX, Chang AL, Oro AE (2012) Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol 199:193-197
12. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480-489
13. Dougan M, Dranoff G (2009) Immune therapy for cancer. Ann Rev Immunol 27:83-117
14. Onishi H, Morisaki T, Baba E, Nakamura M, Inaba S, Kuroki H et al (2011) Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma. Anticancer Res 31:3995-4005
15. + T lymphocytes. J Immunol 169:1869-1875
16. + T cells. J Immunol 169:5451-5457
17. Rowbotham NJ, Hager-Theodorides AL, Furmanski AL, Crompton T (2007) A novel role for hedgehog in T-cell receptor signaling. Cell Cycle 17:2138-2142
18. Syn WK, Witek RP, Curbishley SM, Jung Y, Choi SS, Enrich B et al (2009) Role for hedgehog pathway in regulating growth and function of invariant NKT cells. Eur J Immunol 39:1879-1892
19. + T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol 183:6800-6807
20. Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, Apasov SG et al (2001) Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol 167:6140-6149
21. Hockel S, Schlenger K, Vaupel P, Hockel M (2001) Association between host tissue vascularity and the prognostically relevant tumor vascularity in human cervical cancer. Int J Oncol 19:827-832
22. Ogino T, Onishi H, Suzuki H, Morisaki T, Tanaka M, Katano M (2012) Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions. Cancer Immunol Immunother 61:409-424
23. Lukashev D, Caldwell C, Ohta A, Chen P, Sitkovsky M (2001) Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1α in activated TNK lymphocytes. J Biol Chem 276:48754-48763
24. Lukashev D, Sitkovsky M (2008) Preferential expression of the novel alternative isoform I.3 of hypoxia-inducible factor 1α in activated human T lymphocytes. Hum Immunol 69:421-425
25. Larbi A, Zelba H, Goldeck D, Pawelec G (2010) Induction of HIF-1α and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells. J Leukoc Biol 87:265-273
26. Onishi H, Morisaki T, Baba E, Kuga H, Kuroki H, Matsumoto K et al (2002) Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin Immunol 105:286-295
27. Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M et al (2011) Combinational cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. Anticancer Res 31:2505-2510
28. Morisaki T, Onishi H, Katano M (2012) Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res 32:2241-2248
29. Onishi H, Morifuji Y, Kai M, Suyama K, Iwasaki H, Katano M (2012) Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. Cancer Sci 103:1272-1279
30. Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I et al (2009) Interferon-γ down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 124:1594-1604
31. Onishi H, Kai M, Odate S, Iwasaki H, Morifuji Y, Ogino T et al (2011) Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. Cancer Sci 102:1144-1150